Effect of vitamin E on non-alcoholic fatty liver disease (NAFLD) in reversing the biochemical and radiological hepatic pathology – an interventional study

Divakar R.; Sugirda P; Lenin R.; Henry Daniel Raj T.

doi:10.18231/j.joapr.2021.29.38

Authors

Divakar R. Department of Pharmacology, Government Villupuram Medical College, Villupuram, Tamil Nadu, India, 605601 https://orcid.org/0000-0001-8041-6628
Sugirda P Department of Pharmacology, Government Villupuram Medical College, Villupuram, Tamil Nadu, India, 605601 https://orcid.org/0000-0002-8563-8163
Lenin R. Department of Pharmacology, Government Villupuram Medical College, Villupuram, Tamil Nadu, India, 605601 https://orcid.org/0000-0003-4608-6762
Henry Daniel Raj T. Department of Pharmacology, Government Villupuram Medical College, Villupuram, Tamil Nadu, India, 605601

DOI:

https://doi.org/10.18231/j.joapr.2021.29.38

Keywords:

Non-alcoholic fatty liver disease (NAFLD), Vitamin E (α-tocopherol), Serum transaminases

Abstract

We aimed to assess the effect of Vitamin E on hepatic pathology in terms of liver enzymes and ultrasonographic (USG) findings in Non-alcoholic Fatty liver disease (NAFLD) patients. Vitamin E was administered as α-tocopherol for 12 weeks for 60 patients. Baseline and after 12 weeks of Vitamin E therapy values of anthropometric measures, fasting blood glucose, lipid profile were estimated apart from liver enzymes and USG based assessment of liver size and Hamaguchi score. NAFLD fibrosis score (NFS), a predictor of hepatic fibrosis was evaluated pre and post treatment with Vitamin E. Significant statistical difference was noted in the reduction of Triglycerides, Cholesterol, VLDL and LDL both diabetic and non-diabetic population in our study. ALT and AST normalization was observed and the mean reduction were -38.11 (p <0.001) and -22.4 (p <0.001) respectively due to Vitamin E. Mean liver size was also decreased from 16.05 (SD±1.2) to 13.36 (SD±2.0) after 12 weeks of Vitamin E therapy. However, no significant change in NFS score was noted [baseline – 0.248 (SD±0.78) and at the end of treatment – 0.535 (SD±0.87)], indicating morphological changes were not reversed with Vitamin E. No significant difference observed for mean weight, waist circumference, body mass index (BMI), serum albumin, bilirubin and HDL levels as well as platelet count from baseline to end of treatment. Hence, Vitamin E alone would be useful in the treatment of NAFLD patients even with diabetes and irrespective of biopsy status.

Downloads

Download data is not yet available.

References

Duseja A, Singh SP, Saraswat VA, Acharya SK, et al., Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol, 5(1), 51-68 (2015)

De A, Duseja A. Non-alcoholic fatty liver disease: Indian perspective. Clin Liv Di, 18(3), 158-163 (2021)

Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, Das B, Sahay R, Modi KD. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). J Assoc Physicians India. 61(7), 448-453 (2013)

Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, Baijal R, Lala S, Chaudhary D, Deshpande A. Prevalence of non-alcoholic fatty liver disease: population-based study. Ann Hepato, 6(3), 161-163 (2007)

Anurag L, Aniket S, Shalik J, Amarja L, Dhananjay R, Sachin J. Non-alcoholic fatty liver disease prevalence and associated risk factors--A study from rural sector of Maharashtra. Trop Gastroenterol, 36(1), 25-30 (2015)

Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology, 51, 1593‐1602 (2010)

Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res, 45(1), 20-28 (2015)

Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol, 105(7), 1567-1573 (2010)

Gambino R, Musso G and Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal, 15, 1325–1365 (2011)

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 65(8), 1038-1048 (2016)

Gitto S, Vitale G, Villa E, Andreone P. Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract, 2015, 1-14 (2015)

Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol, 24(30),3361-3373 (2018)

Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol,53(3),362-376 (2018)

Raza S, Tewari A, Rajak S, Sinha RA. Vitamins and non-alcoholic fatty liver disease: A Molecular Insight. Liver Res, 5(2), 62-71 (2021)

El Hadi H, Vettor R, Rossato M. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? Antioxidants (Basel), 7(1),12 (2018)

Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care, 15(6),641-648 (2012)

Abdel-Maboud M, Menshawy A, Menshawy E, Emara A, Alshandidy M, Eid M. The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Therap Adv Gastroenterol, 13,1–18(2020)

Ferraioli, Giovanna, and Livia Beatriz Soares Monteiro. Ultrasound-based techniques for the diagnosis of liver steatosis. World journal of gastroenterology,25(40),6053-6062 (2019)

Bhadoria AS, Kasar PK, Toppo NA. Validation of Indian diabetic risk score in diagnosing type 2 diabetes mellitus against high fasting blood sugar levels among adult population of central India. Biomed J, 38(4),359-360 (2015)

Shah SN, Billimoria AR,Kamath SA, et al., Indian Guidelines on Hypertension – III. Hypertension Society of India. J Clin Prev Cardiol, 2(3),128-61 (2013)

Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol, 102, 2708-2715 (2007)

Treeprasertsuk S, Björnsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol, 19(8),1219-1229 (2013)

Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther, 15(10), 1667-1672 (2001)

Wang CL, Liang L, Fu JF, Zou CC, Hong F, Xue JZ, Lu JR, Wu XM. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol, 14(10),1598-1602 (2008)

Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol, 98(11), 2485-2490 (2003)

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med, 362(18),1675-1685 (2010)

Pietu F,Guillaud O, Walter T, Vallin M, Hervieu V, Scoazec JY, Dumortier J. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results. Clin. Res. Hepatol. Gastroenterol, 36,146–155 (2012)

Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA, 305, 1659–1668 (2011)

Singh SP, Nayak S, Swain M, Rout N, Mallik RN, Agrawal O, Meher C, Rao M. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol, 25(2),76-79 (2004)

Foster, T.; Budoff, M.J.; Saab, S.; Ahmadi, N.; Gordon, C.; Guerci, A.D. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St Francis Heart Study randomized clinical trial. Am. J. Gastroenterol, 106, 71–77 (2011)

Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, Tio F, Suman A, Orsak BK, Hecht J, Cusi K. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care, 42(8), 1481-1488 (2019)

Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E,Rizzetto M, Marchesini G. A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease. The American Journal of Gastroenterology, 100:1082-1090 (2005)

Parikh P, Ingle M, Patel J, Bhate P, Pandey V, Sawant P. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients. Saudi J Gastroenterol, 22(3),192-197 (2016)

Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN). Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 38(2),134-143 (2013)

Mohammad A, Falahi E, Barakatun-Nisak MY, Hanipah ZN, Redzwan SM, Yusof LM, Gheitasvand M, Rezaie F. Systematic review and meta-analyses of vitamin E (alpha-tocopherol) supplementation and blood lipid parameters in patients with diabetes mellitus. Diabetes Metab Syndr, 15(4), 102158 (2021)

Rezasoltani P, Elliyoun N, Ziaie T, Sobhani A, Kazemnezhjad Leyli E, Kazemi Aski S. Double-Blind Controlled Trial of Vitamin E Effects on Serum Lipid Profile in Menopausal Women. Diabetes Metab Syndr Obes, 14,1053-1060 (2021)

Wang Q, Sun Y, Ma A, Li Y, Han X, Liang H. Effects of vitamin E on plasma lipid status and oxidative stress in Chinese women with metabolic syndrome. Int J Vitam Nutr Res, 80(3),178-187 (2010)

Grover M, Rutkowski R, Nashelsky J. FPIN's Clinical Inquiries: evaluation of elevated serum transaminase levels. Am Fam Physician, 86(8),1-2. (2012)

Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr, 136(6),734–738 (2000)

Madan K, Batra Y, Gupta DS, Chander B, Anand Rajan KD, Singh R, Panda SK, Acharya SK. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian J Gastroenterol, 24(6),251-255 (2005)

Mohan Prasad, V., Rahate, P., Bohri, H., Mahapatra, J., Mungantiwar, A., Srivastava, P., Bhatt, N., Patel, D., Roy, S. and Qamra, A.Real World Evidence of Safety and Effectiveness of Combination of Vitamin E and Fraxinus excelsior in Treatment of Indian Patients with Nonalcoholic Fatty Liver Disease. Open Journal of Gastroenterology, 10,14-22 (2020)

Aller R, Izaola O, Gómez S, Tafur C, González G, Berroa E, Mora N, González JM, de Luis DA. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci, 16,3118-3124 (2015)

Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology, 48(1), 19-28 (2008)

Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A; Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol, 12, 1537-1543 (2006)

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 55(6), 2005–2023 (2012)

Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Role of Vitamin E in the Treatment of NAFLD. Diseases, 6(4), 86 (2018)

Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, Nakade Y, Ito K, Fukuzawa Y, Yoneda M. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition, 31(7-8), 923-930 (2015)

Usman M, Bakhtawar N. Vitamin E as an Adjuvant Treatment for Non-alcoholic Fatty Liver Disease in Adults: A Systematic Review of Randomized Controlled Trials. Cureus, 12(7), e9018 (2020)

Amanullah I, Khan YH, Anwar I, et al. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgraduate Medical Journal, 95,601-611 (2019)

X. Shu, L. Zhang and G. Ji, Vitamin E Therapy in Non-Alcoholic Fatty Liver Disease. International Journal of Clinical Medicine, 5(3), 87-92 (2014)

Vélez M, Jhonathan Ferney, Crespo H, Gustavo Amador, & Restrepo G, Juan Carlos. Vitamin E Treatment for Patients with Nonalcoholic Steatohepatitis. Revista colombiana de Gastroenterología, 29(4), 397-403 (2014)

Markus S, Robert JG, Pamela MR, Christophe T, Tobias K. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ, 341, c5702 (2010)

Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann

Intern Med, 142(1), 37-46 (2005)

Abner EL, Schmitt FA, Mendiondo MS, Marcum JL, Kryscio RJ. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci, 4(2),158-170 (2011)